AMERISE
NSE: AMERISE

Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Key Statistics

Investment Rating

  • Master Rating:
  • Amerise Biosciences has an operating revenue of Rs. 10.56 Cr. on a trailing 12-month basis. An annual revenue growth of 5735% is outstanding, Pre-tax margin of 6% is okay, ROE of 9% is fair but needs improvement. From an O'Neil Methodology perspective, the stock has an EPS Rank of 29 which is a POOR score indicating inconsistency in earnings, a RS Rating of 6 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 143 indicates it belongs to a poor industry group of Finance-Blank Check and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Result Highlights

Synopsis

BSE-Finance-Blank Check

Amerise Biosciences belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 0.00 Cr. and Equity Capital is Rs. 6.61 Cr. for the Year ended 31/03/2021. Amerise Biosciences Ltd. is a Public Limited Listed company incorporated on 27/08/1984 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L29199GJ1984PLC007195 and registration number is 007195.
  • Market Cap
  • 6
  • Sales
  • 8
  • Shares in Float
  • 6.61
  • No of funds
  • Yield
  • Book Value
  • 1.13
  • U/D Vol ratio
  • 0.8
  • LTDebt / Equity
  • 1
  • Alpha
  • -0.18
  • Beta
  • 0.28

  • Owner Name
  • Jun-22
  • Mar-22
  • Dec-21
  • Sep-21
  • Individual Investors
  • 72.28%
  • 57.53%
  • 13.01%
  • Others
  • 27.72%
  • 42.47%
  • 86.99%

Management

  • Name
  • Designation
  • Ms. Manisha Maneklal Patel
  • Director
  • Mr. Dineshkumar Tribhovanbhai Rathod
  • WholeTime Director & CFO
  • Mr. Niraj Vaghela
  • Director

Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

FAQs

What is Share Price of ?

share price is ₹ As on 09 August, 2022 | 18:24

Q1FY23